Autism is an agonizing puzzle, a complex mixture of genetic and environmental factors. One piece of this puzzle that has emerged in recent years is a biochemical cascade called the mTOR pathway that regulates growth in the developing brain.
A mutation in one of the genes that controls this pathway, PTEN (also known as phosphatase and tensin homolog), can cause a particular form of autism called macrocephaly/autism syndrome.
Using an animal model of this syndrome, scientists from the Florida campus of The Scripps Research Institute (TSRI) have discovered that mutations in PTEN affect the assembly of connections between two brain areas important for the processing of social cues: the prefrontal cortex, an area of the brain associated with complex cognitive processes such as moderating social behavior, and the amygdala, which plays a role in emotional processing.
When PTEN is mutated, we find that neurons that project from the prefrontal cortex to the amygdala are overgrown and make more synapses. In this case, more synapses are not necessary a good thing because this contributes to abnormal activity in the amygdala and deficits in social behavior."
TSRI Associate Professor Damon Page.
The study was published on November 15 by the journal Nature Communications. The study also showed that targeting the activity of the mTOR pathway shortly after birth, a time when neurons are forming connections between these brain areas, can block the emergence of abnormal amygdala activity and social behavioral deficits.
Likewise, reducing activity neurons that project between these areas in adulthood can also reverse these symptoms.
Given that the functional connectivity between the prefrontal cortex and amygdala is largely conserved between mice and humans. We anticipate the therapeutic strategies suggested here may be relevant for individuals on the autism spectrum."
TSRI Graduate Student Wen-Chin Huang, the first author of the study.
Although caution is warranted in extrapolating findings from animal models to humans, these findings have implications for individualized approaches to treating autism.
"Even within individuals exposed to the same risk factor, different strategies may be appropriate to treat the symptoms of autism in early development versus maturity," said Page.
The Scripps Research Institute